Recursion Pharmaceuticals (RXRX) Return on Capital Employed (2021 - 2026)
Recursion Pharmaceuticals (RXRX) posted Return on Capital Employed of 45.83% for Q1 2026, up 8.85% on a QoQ basis from 50.28% in Q4 2025, and up 66.0% year-over-year from 27.61% in Q1 2025.
Recursion Pharmaceuticals (RXRX) Return on Capital Employed (2021 - 2026) Analysis & Trends
Recursion Pharmaceuticals' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 45.83% for Q1 2026.
- Quarterly Return on Capital Employed rose 66.0% year-over-year to 45.83% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 45.83% (up 66.0% YoY) and the FY2025 annual result came in at 49.34%, up 612.0% from the prior year.
- Return on Capital Employed was 45.83% for Q1 2026 at Recursion Pharmaceuticals, up from 50.28% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 35.5% in Q1 2022 and bottomed at 70.8% in Q1 2024.
- A 5-year average of 52.55% and a median of 51.61% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed plunged 2542 bps — and 2025, when it surged 2431 bps.
- Recursion Pharmaceuticals' Return on Capital Employed stood at 44.18% in 2022, then plunged by 44 bps to 63.75% in 2023, then increased by 17 bps to 53.22% in 2024, then climbed by 6 bps to 50.28% in 2025, then grew by 9 bps to 45.83% in 2026.
- Business Quant data shows RXRX's Return on Capital Employed at 45.83% in Q1 2026, 50.28% in Q4 2025, and 60.51% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Recursion Pharmaceuticals | 1.59 Bn | 933.22 Mn | -6.02 Mn | -45.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.83% |
| Dec 31, 2025 | -50.28% |
| Sep 30, 2025 | -60.51% |
| Jun 30, 2025 | -57.00% |
| Mar 31, 2025 | -46.48% |
| Dec 31, 2024 | -53.22% |
| Sep 30, 2024 | -61.37% |
| Jun 30, 2024 | -68.08% |
| Mar 31, 2024 | -70.80% |
| Dec 31, 2023 | -63.75% |
| Sep 30, 2023 | -56.27% |
| Jun 30, 2023 | -51.61% |
| Mar 31, 2023 | -45.37% |
| Dec 31, 2022 | -44.18% |
| Sep 30, 2022 | -44.67% |
| Jun 30, 2022 | -38.49% |
| Mar 31, 2022 | -35.50% |
| Dec 31, 2021 | -31.09% |
| Sep 30, 2021 | -22.56% |
| Jun 30, 2021 | -26.21% |